Using isolated rat aortic rings perfused with Krebs-Henseleit saline, the vascular effects of angiotensin (1-7) (Ang [1-7]) and its interactions with angiotensin II (Ang II) were investigated.
Introduction
Numerous experimental data have demonstrated that the octapeptide angiotensin II (Ang II) is not the only biologically active component of the tissue and circulating renin-angiotensin systems (RAS).
Similar, but less potent, physico-pharmacological properties have been demonstrated for angiotensin III (2) (3) (4) (5) (6) (7) (8) and angiotensin IV (3) (4) (5) (6) (7) (8) , 1 which are mediated via AT 1 -and AT 2 -receptors. [2] [3] [4] Newer angiotensin fragments from the RAS have been identified as metabolism products of angiotensin I (1-10) and II (1) (2) (3) (4) (5) (6) (7) (8) , having completely different biological properties. Among these are the nonapeptide angiotensin (1) (2) (3) (4) (5) (6) (7) (8) (9) , which produces central dipsogenic effects 5 and the heptapeptide angiotensin (1-7) (Ang [1] [2] [3] [4] [5] [6] [7] ), which generates vascular miorelaxing actions. 6, 7 Ang (1-7), discovered by Schiavone et al., 8 is formed from angiotensin I (Ang I) or Ang II by either a carboxypeptidase called conversionenzyme 2, 9 or by tissue endopeptidases. 10 The resulting Ang (1-7) acts on a specific receptor, 11, 12 which induces the relaxation of coronary arteries via endothelial prostaglandin release, 13, 14 kinin release 15 and nitric oxide (NO). 16, 17 The myorelaxing and hypotensive properties of Ang (1-7) result both from the potentiation of the dilating effects of bradykinin 18 and from inhibition of angiotensinconverting enzyme (ACE), 19 as well as by antiproliferative effects on vascular smooth muscle. 20 Through these multiple pathways, Ang (1-7) is involved as counter-regulatory factor within the RAS. 7 ACE inhibition, by blocking the formation of Ang II, induced a 25-50-fold increase of circulating Ang (1-7) in patients with high blood pressure (BP), 21 due to the shift in the conversion of Ang I to Ang (1) (2) (3) (4) (5) (6) (7) . This inhibited the vasoconstriction induced by angiotensins I, II and III more intensely in rat aortic rings with normal endothelium than in de-endothelised ones. 22 Vasoconstriction induced by norepinephrine or phenylephrine was also inhibited by ACE inhibition. 23 The direct and indirect vasodilator effects of Ang (1-7) contribute to the antihypertensive and antiproliferative actions of ACE inhibitors. 24 As a result of these data, a new hypothesis has recently arisen, concerning a possible balance between the vasoconstrictor and hypertensive properties of Ang II and the vasodilating properties of Ang (1-7), as an intrinsic system for braking, modulating, self-regulating and controlling RAS vascular actions. 24, 25 In humans, Ang (1-7) dose-dependently induces biphasic vascular reactions in forearm resistance vessels.At low doses,Ang (1-7), injected in the humeral artery, induces an increase in forearm blood flow, due to both direct vasodilation and to reduction of the vasoconstricting effects of Ang II. In contrast, high doses of Ang (1-7), which shows some affinity for the AT 1 -receptor, 26 induces constriction of resistance vessels and reduces forearm blood flow. 27 Dose-dependent biphasic effects were also observed on BP in rats, as well as in rabbit aorta rings 28 and rat renal vessels. 29 In the light of these controversial data, we studied the interactions at the arterial level between the two vasoactive angiotensin peptides, emphasising the biphasic properties of Ang (1-7) and its influence on the vasoconstricting effects of Ang II.
Materials and methods
The experiments were performed in vitro on isolated thoracic aortic rings taken from male Wistar rats (180-200 g bodyweight) kept under normal laboratory conditions. After killing by decapitation and exsanguination, the thoracic aorta was The rings, either intact or with the endothelium removed by gentle rubbing with stainless steel wire, were set in an organ bath (4 ml) and perfused with Krebs-Henseleit saline at 38°C and bubbled with 95% O 2 /5% CO 2 . The aortic rings were stretched with 2 g of preload and left to equilibrate for 60 minutes, before the beginning of the experiment. The experiments were performed in series, using coupled preparations of aortic rings, both with and without endothelium, concerning the direct and indirect effects of Ang (1-7) and its vascular interrelations with Ang II.
The testing of the vascular reactivity according to the integrity of the endothelium of the rings was made with the vasoconstrictor α-adrenergic agonist, phenylephrine (10 -7 -10 -5 M), and with carbachol (10 -5 -10 -6 M), which releases myorelaxing endothelial NO. 30 The simultaneous recording of the contractions was performed using four isometric force transducers coupled with a computer acquisition system.
The vascular effects of Ang (1-7), both directly and indirectly, on the vasoconstricting action of Ang II were tested under basal relaxation conditions and/or precontracted with phenylephrine, before and after the administration of the angiotensin receptor inhibitors, losartan, PD 123319 and A779.
Ang (1-7) was used in variable concentrations (10 -8 -10 -5 M),Ang II in doses of 10 -6 -10 -5 M and the angiotensin receptor blockers in doses according to a report by Dina and Jafari. 4 In order to avoid tachyphylaxis of the preparations, the administration of angiotensins was made at time intervals large enough (90-120 minutes) to avoid tachyphylaxis and after repeated wash-outs.
Ang (1-7),Ang II, losartan and PD 123319 were obtained from Sigma Co., and Ang (1-7) and A779 from the Bachem Company.
The changes in the contractility of the vascular smooth muscle were statistically analysed, calculating the percentile variations of the means and SEM using t-test and ANOVA.The results were presented as representative individual traces, tables and percentile graphs.
Results
In an initial series of experiments, we investigated the effects of Ang (1-7) on phenylephrine-precontracted rings. After stretching (1.5-2 g) and equilibration for 45-60 minutes, both normal and denuded (de-endothelised) aortic rings were contracted to test the myorelaxing action of Ang (1-7) in progressive doses. In agreement with data from the literature 10, 22, 31 Ang (1-7) induced the relaxation of the aortic smooth muscle precontracted with phenylephrine (10 -7 M), more intensely in normal than in denuded rings, as shown in the example (Figure 1 ). Since the relaxing properties of Ang (1-7) appeared greater for high doses (10 -6 -10 -5 M) on precontracted preparations, we then investigated its influence on the vasoconstriction produced by Ang II under basal conditions in normal and deendothelised aortic rings.
Ang (1-7), in most cases, induced either a small decrease in the basal tone of aortic smooth muscle, followed by a reduction of the vasopressor effects of Ang II, or an obvious vasoconstricting effect.
In the first case, while testing the constricting activity of Ang II on the basal vascular tone of aortic rings pretreated with Ang (1-7), a significant reduction of its pressor effects was observed, both in normal and in de-endothelised preparations.An example of the inhibiting influence of Ang (1-7) on the pressor effects of Ang II on a de-endothelised ring is shown in Figure 2 .
The inhibition of the vasoconstricting action of Ang II by Ang (1-7) did not appear more obvious in normal preparations than in de-endothelised ones, as shown in Table 1 . Data concerning the eventual involvement of the vehicle for both Ang II and Ang (1-7) are not presented, because the substances were dissolved in the same saline (Krebs-Henseleit) that was used for perfusion in all experiments. Ang (1-7) induced a significant reduction in the vasoconstricting action of Ang II, both on normal aortic rings (61.96+9.4 to 24.75+10.69) and on de-endothelised ones (from 56.4+6.59 to 29.98+3.11). The inhibiting effect of Ang (1-7) was not different in normal and de-endothelised rings (29.98+3.11 and 24.79+10.19 respectively).
The vasopressor effects of repeated administration of Ang (1-7) on an aortic ring with intact endothelium are shown in Figure 3 .
It is also worthy of note that the vasopressor effect of Ang (1-7) was persistent in repeated administrations at relatively short intervals (10-15 minutes), suggesting the lack of tachyphylaxis, a well-known phenomenon for Ang II. Also, a persistence of the pressor effects of Ang (1-7) on the precontraction induced by Ang II was seen.
The inhibition of AT 1 -receptors with losartan (10 -5 M) reduced the vasoconstricting actions of PAPER Unlike losartan, 10 -5 M PD 123319, an inhibitor of AT 2 -receptors, did not significantly influence the vascular actions of Ang (1-7), or its effects on Ang II (Figure 4 ).
However, A779, an inhibitor of the Ang (1-7) receptors, significantly reduced the myorelaxing effects of Ang (1-7) , without inhibiting its constricting properties ( Figure 5 ).
Discussion
These results demonstrated that Ang (1-7) produced, in our experimental conditions, biphasic effects on rat aortic rings.The relatively large concentrations of Ang (1-7) that we used produced both vascular myorelaxing actions, accompanied by the inhibition of the pressor effects of Ang II, and also stimulation of the basal contractility of aortic rings, without significant changes on the vasoconstriction induced by Ang II.
Compared with the relaxing and vasodilating properties of Ang (1-7), which have been widely studied in the last years, its vasopressor actions have been far less investigated. Dose-dependent biphasic effects were obtained on rat BP, 28 on the human forearm resistance vessels 27 and rat renal vessels. 29 The mechanism through which these effects are produced is complex, being dependent on both the presence of at least two types of Ang (1-7) receptor, and also on the involvement of the endothelial factors that modulate vascular smooth muscle reactivity.
The two types of angiotensin receptors involved in the biphasic responses to Ang (1-7) are the specific Ang (1-7) receptor, 11, 12 blocked by the selective antagonist A779, and the AT 1 -receptor, inhibited by losartan. 3 Whether the activation of these receptors by Ang (1-7) was produced via a direct or an indirect modulator pathway remains to be established. A possible direct pathway is suggested by the fact that Ang (1-7) acts as a partial agonist for AT 1 -receptors and also by the lack of difference between the inhibition of Ang II responses in normal and de-endothelised preparations.
Referring to the functional implications of the vascular properties of Ang (1-7), published data 7, 25 suggest the existence of an intrinsic compensatory mechanism that counter-regulates, balances and brakes the pressor effects of RAS, using Ang (1) (2) (3) (4) (5) (6) (7) to protect against the vascular effects of the vasoconstrictor agent,Ang II. Converting enzyme inhibition 19 and reduction of α-adrenergic vasoconstriction 23 might also contribute to the functionality of this compensatory mechanism.
Correlating the data in the literature concerning the affinity of large doses of Ang (1-7) for AT 1 -receptors 26 with our results, we consider that it intervenes as a counter-regulation factor, not only for the vasopressor properties of Ang II, but also as a braking factor for the vasodilation induced by the excess of its own direct and indirect modulator actions.Thus, Ang (1-7) seems to contribute to the self-regulation and re-establishment of the vascular imbalances induced both by the excess and deficit of circulating Ang II. The involvement of the biphasic effects of Ang (1-7) in the modulation and counter-regulation of the pressure properties of circulating Ang II is presented in Figure 6 .
Besides its predominantly vasodilator (direct and indirect) effects,Ang (1-7) could act, not only as a braking factor of the vasopressor action of Ang II, but also as a vasoconstricting factor necessary to the self-regulation of its own activity, for the modulation and rebalancing of the basal vascular tone. This theory will be the subject of further research by our group. 
